CAKI-1细胞

Caki-1/Caki-1细胞系/Caki-1细胞株/Caki-1人肾透明细胞癌

Cell line name Caki-1

Synonyms CAKI-1; CaKi-1; caki-1; CAKI.1; CAKI 1; CAKI1; Caki1

Accession CVCL_0234

Resource Identification Initiative To cite this cell line use: Caki-1 (RRID:CVCL_0234)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: MD Anderson Cell Lines Project.

Part of: NCI-60 cancer cell line panel.

From: Memorial Sloan Kettering Cancer Center; New York; USA.

Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK1980-534.

Population: Caucasian.

Virology: Susceptible to infection by SARS coronavirus 2 (SARS-CoV-2) (COVID-19) (PubMed=37668370).

Virology: Susceptible to infection by human coronavirus 229E (HCoV-229E), Middle East respiratory syndrome-related coronavirusinfluenza A virus and respiratory syncytial virus (RSV) (PubMed=37668370).

Doubling time: 36 hours (PubMed=25984343); ~40-60 hours (DSMZ=ACC-731); 39 hours (NCI-DTP=CAKI-1).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Fluorescence phenotype profiling.

Omics: GPI-anchored proteins analysis by proteomics.

Omics: lncRNA expression profiling.

Omics: Metabolome analysis.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Derived from site: Metastatic; Skin; UBERON=UBERON_0002097.

PubMed=10700174; DOI=10.1038/73432

Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O.

Systematic variation in gene expression patterns in human cancer cell lines.

Nat. Genet. 24:227-235(2000)

 

PubMed=10723130; DOI=10.1038/sj.onc.1203449

Alimov A., Kost-Alimova M., Liu J., Li C.-D., Bergerheim U.S.R., Imreh S., Klein G., Zabarovsky E.R.

Combined LOH/CGH analysis proves the existence of interstitial 3p deletions in renal cell carcinoma.

Oncogene 19:1392-1399(2000)

 

PubMed=10929426; DOI=10.1007/s002400000103

Shintaku I., Kawagoe N., Yutani S., Hoshi S., Orikasa S., Yoshizumi O., Itoh K.

Expression of the SART1 tumor rejection antigen in renal cell carcinoma.

Urol. Res. 28:178-184(2000)

 

PubMed=11146448; DOI=10.1002/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S

Kondo K.-i., Yao M., Kobayashi K., Ota S., Yoshida M., Kaneko S., Baba M., Sakai N., Kishida T., Kawakami S., Uemura H., Nagashima Y., Nakatani Y., Hosaka M.

PTEN/MMAC1/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines.

Int. J. Cancer 91:219-224(2001)

 

PubMed=15604581; DOI=10.1159/000081597

Ikemoto S., Sugimura K., Yoshida N., Kuratsukuri K., Wada S., Nakatani T.

Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with interferon-alpha in renal cell carcinoma cell lines.

Urol. Int. 73:348-353(2004)

 

PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742

Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M.

HLA class I and II genotype of the NCI-60 cell lines.

J. Transl. Med. 3:11.1-11.8(2005)

 

PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832

Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mir, Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.

Mutation analysis of 24 known cancer genes in the NCI-60 cell line set.

Mol. Cancer Ther. 5:2606-2612(2006)

 

PubMed=17212712; DOI=10.1111/j.1399-0039.2006.00725.x

Komohara Y., Suekane S., Noguchi M., Matsuoka K., Yamada A., Itoh K.

Expression of APOBEC3G in kidney cells.

Tissue Antigens 69:95-98(2007)

 

PubMed=17804913; DOI=10.1159/000107804

Glube N., Giessl A., Wolfrum U., Langguth P.

Caki-1 cells represent an in vitro model system for studying the human proximal tubule epithelium.

Nephron Exp. Nephrol. 107:e47-e56(2007)

 

PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356

Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N.

DNA fingerprinting of the NCI-60 cell line panel.

Mol. Cancer Ther. 8:713-724(2009)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)